Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.
(2022) Transplantation — Vol. 106, n° 1, p. e107-e108 (2022)
Files
Details
- Authors
- Abstract
- (en) Kidney transplant recipients (KTRs) are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and may remain at risk after complete vaccination because of poor response rate. Neutralizing monoclonal antibodies (Abs) have been shown to be safe and efficient in reducing viral load in immunocompetent outpatients with coronavirus disease 2019 (COVID-19). In immunocompromised patients, including solid organ transplant recipients, few reports have reported similar results. [...]
- Affiliations
Citations
Fernandes, G., Devresse, A., Scohy, A., Yombi, J. C., Belkhir, L., De Greef, J., Darius, T., Buemi, A., Kabamba-Mukadi, B., Goffin, E., & Kanaan, N. (2022). Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium. Transplantation, 106(1), e107-e108. https://doi.org/10.1097/TP.0000000000003974 (Original work published 2022)